BioCentury
ARTICLE | Clinical News

AbbVie's PARP fails to show survival benefit

December 8, 2016 12:06 AM UTC

Veliparib (ABT-888) from AbbVie Inc. (NYSE:ABBV) missed the primary endpoint of a Phase II trial to treat patients with recurrent or metastatic breast cancer with BRCA1 or BRCA2 mutations, according to two abstracts posted on the web site of the San Antonio Breast Cancer Symposium (SABCS). The abstracts showed combinations including the oral PARP inhibitor failed to significantly improve progression-free survival (PFS) vs. placebo.

One abstract showed that veliparib plus carboplatin and paclitaxel led to PFS of 14.1 vs. 12.3 months for placebo plus carboplatin and paclitaxel (p=0.231). The veliparib combination also failed to significantly improve overall survival (OS); however, it did significantly improve overall response rate (ORR). OS and ORR were secondary endpoints...

BCIQ Company Profiles

AbbVie Inc.

BCIQ Target Profiles

PARP